Marco Mangiafico

Dr. Marco Mangiafico

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2016 in Angiology
Verified
Journal Article
Closed access
Salvatore Santo SignorelliSalvatore Santo Signorelli
Salvatore Santo Signorelli
GVGuido Li Volsi
Guido Li Volsi
APAlessandro Pitruzzella
Alessandro Pitruzzella
VFValerio Fiore
Valerio Fiore
MMMarco Mangiafico
Marco Mangiafico
Giovanni Li VoltiGiovanni Li Volti
Giovanni Li Volti
Some emerging risk factors such as oxidative stress biomarkers and microRNAs (miRs) may add additional value to the established risk factors for peripheral artery disease (PAD). We enrolled 27 patients with PAD and 27 age-matched controls. We examined the levels of a series of miRs (miR-130a, miR-27b, and miR-210) in serum samples. The level of well-established oxidative stress biomarkers, such as lipid hydroperoxides, isoprostanes, hemeoxygenase-1 (HO-1) and reduced glutathione, was also measured in plasma and their relationship with the miRs was determined. Levels of miR-130a, miR-27b, and miR-210 were significantly increased in patients with PAD when compared to the controls. The level of miR-130 was positively correlated with body mass index, whereas miR-210 was inversely associated with pain-free walking distance (PfWD). None of the evaluated miRs was associated with lowered PfWD of patients with PAD (stage IIa > 250 m, IIb < 250 m) or oxidative stress parameters. In conclusion, our findings suggest the need for more research to assess if miRs can serve as useful markers for the early diagnosis and monitoring of PAD.

1 January 2006 in Age and Ageing
Verified
Journal Article
Open access
PDF file
RMRoberto Antonio Mangiafico
Roberto Antonio Mangiafico
FSFabrizio Sarnataro
Fabrizio Sarnataro
MMMarco Mangiafico
Marco Mangiafico
CFCarmelo Erio Fiore
Carmelo Erio Fiore
Background and purpose: asymptomatic peripheral arterial disease (APAD), a highly prevalent condition in the general older population, is associated with an increased risk of cerebrovascular events because of co-existing clinical or subclinical cerebral atherosclerosis. The purpose of this study was to investigate whether cognitive function is impaired in stroke- and transient ischaemic attack-free patients with APAD, and whether inflammatory and haemostatic markers are associated independently with neuropsychological performance. Methods: cognitive performances of 164 well-functioning, community-dwelling patients with APAD were compared with those of 164 age-, gender- and education-matched healthy control subjects on six neuropsychological tests. Levels of C-reactive protein (CRP), D-dimer and fibrinogen were also analysed in all participants. Results: patients with APAD scored significantly worse (P<0.0001) than control subjects on five cognitive tests assessing domains of verbal working memory, attention, perceptuomotor speed, mental flexibility, visuoconstructive skills and visual memory. Multiple linear regression analyses showed that CRP and D-dimer were significant, independent predictors of poorer performances on four and three cognitive tests, respectively, within patients with APAD. Conclusions: patients with APAD show cognitive impairment in a range of psychometric tests, and CRP and D-dimer appear to be independent negative predictors of some cognitive performances. These findings suggest the need for screening for APAD among at-risk subjects in order to identify patients to be treated for prevention of functional decline and dementia. They also support the hypothesis that inflammation and hypercoagulability are implicated in the pathophysiology of cognitive dysfunction associated with APAD.

20 February 2006 in Journal of Bone and Mineral Metabolism
Verified
Journal Article
Closed access
PDF file
RMRoberto Antonio Mangiafico
Roberto Antonio Mangiafico
EREnzo Russo
Enzo Russo
SRStefania Riccobene
Stefania Riccobene
PPPietra Pennisi
Pietra Pennisi
MMMarco Mangiafico
Marco Mangiafico
CFCarmelo Erio Fiore
Carmelo Erio Fiore

Verified
Journal Article
Open access
PDF file
MMMarco Mangiafico
Marco Mangiafico
ACAndrea Caff
Andrea Caff
LCLuca Costanzo
Luca Costanzo
Coronavirus disease 2019 (COVID-19) is associated with an increased risk of venous thromboembolism (VTE) and coagulopathy, especially in critically ill patients. Endothelial damage induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is emerging as a crucial pathogenetic mechanism for the development of complications in an acute phase of the illness and for several postdischarge sequalae. Heparin has been shown to have a positive impact on COVID-19 due to its anticoagulant function. Moreover, several other biological actions of heparin were postulated: a potential anti-inflammatory and antiviral effect through the main protease (Mpro) and heparansulfate (HS) binding and a protection from the damage of vascular endothelial cells. In this paper, we reviewed available evidence on heparin treatment in COVID-19 acute illness and chronic sequalae, focusing on the difference between prophylactic and therapeutic dosage.

1 November 2011 in Current Vascular Pharmacology
Verified
Journal Article
Closed access
PDF file
RMRoberto A. Mangiafico
Roberto A. Mangiafico
MMMarco Mangiafico
Marco Mangiafico
Atherosclerotic critical limb ischemia (CLI) is manifested by ischemic rest pain, non-healing ulcers or gangrene. The incidence of CLI is estimated to be approximately 500-1000 new cases per year per million people and is expected to grow in developed countries as the population ages with an increasing prevalence of diabetes. Patients diagnosed with CLI are at very high risk of major amputation and cardiovascular morbidity and mortality and experience poor physical function and quality of life. The goals of treatment for CLI are relieving ischemic pain, healing ulcers, preventing limb loss, improving patient function and quality of life, and prolonging survival. Prompt surgical or endovascular revascularization is currently recommended for limb salvage in CLI. All patients with CLI should receive cardiovascular risk reduction therapies, focused on optimizing antiplatelet therapy and risk factor management, to reduce cardiovascular event rates. Adjunctive pharmacotherapy with antithrombotic drugs, statins, and beta-blockers is critical to decrease perioperative cardiovascular complications in patients undergoing surgical vascular reconstruction and enhance postrevascularization arterial and graft patency. In non-reconstructable patients with stable pain and tissue loss, evidence suggests that prostanoids, dedicated wound care programs, and several mechanical devices, such as spinal cord stimulation, intermittent pneumatic compression, and hyperbaric oxygen therapy, can alleviate ischemic symptoms and improve limb salvage. Current medical armamentarium used in treating ischemic wounds also includes ultrasound and negative pressure wound therapy. Therapeutic neovascularization, including gene- and cell-based approaches, is a novel promising tool in the management of CLI under ongoing investigation.

4 August 2007 in Osteoporosis International
Verified
Journal Article
Closed access
PDF file
RMR. A. Mangiafico
R. A. Mangiafico
CAC. Alagona
C. Alagona
PPP. Pennisi
P. Pennisi
NPN. Parisi
N. Parisi
MMMarco Mangiafico
Marco Mangiafico
CFC. E. Fiore
C. E. Fiore